Protalix BioTherapeutics (PLX) Receivables - Net (2010 - 2026)

Protalix BioTherapeutics has reported Receivables - Net for 17 years, with the latest figure at $2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 37.13% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.9 million (down 37.13% YoY), and the FY2025 full-year result was $8.8 million, up 203.88% from the prior year.
• Receivables - Net for Q1 2026 stood at $2.9 million, down from $8.8 million in the prior quarter.
• The five-year high for Receivables - Net was $14.4 million in Q3 2025, with the low at $1.3 million in Q1 2023.
• Average Receivables - Net over 5 years is $5.9 million, with a median of $4.7 million recorded in 2025.
• Year-over-year, Receivables - Net slumped 77.93% in 2023 and jumped 557.18% in 2025.
• Tracing PLX's Receivables - Net over 5 years: stood at $4.6 million in 2022, then rose by 14.96% to $5.3 million in 2023, then sank by 44.82% to $2.9 million in 2024, then soared by 203.88% to $8.8 million in 2025, then tumbled by 66.75% to $2.9 million in 2026.
• The last three Receivables - Net figures came in at $2.9 million (Q1 2026), $8.8 million (Q4 2025), and $14.4 million (Q3 2025), per Business Quant data.

Peer Comparison